A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer
This is a Phase II, multicenter, randomized, blinded, placebo-controlled study designed to evaluate the safety and efficacy of combining bevacizumab with sunitinib relative to placebo with sunitinib in patients with metastatic RCC who have not received prior systemic therapy for metastatic disease. The study will enroll approximately 100 patients at approximately 20 centers in the United States.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : sunitinib
- drug : Bevacizumab
- drug : placebo
Phase: Phase 2
Ages Eligible For Study:
- Signed Informed Consent Form - Histologically confirmed metastatic RCC - Measurable disease, as defined by RECIST - Age ? 18 years - ECOG performance status of 0 or 1 - Prior nephrectomy - Ability and capacity to comply with study and follow-up procedures